The core of the claim is confirmed by the primary regulatory artifact.

The FDA-approved label states that VIZZ is a cholinergic agonist indicated for the treatment of presbyopia in adults, dosed by instilling one drop in each eye, waiting 2 minutes, then instilling a second drop in each eye once daily from the same single-dose vial. It is supplied as aceclidine 1.44% in a single-dose vial.

On mechanism, the label's own clinical pharmacology section states that aceclidine is a cholinergic muscarinic agonist that stimulates muscarinic receptors located on smooth muscles, that VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation, and that VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. The pinhole description in the claim is therefore not marketing language alone; it is the regulator-approved label's own wording.

On duration, the label's clinical studies section states that Figure 1 and Figure 2 demonstrate the onset of the VIZZ effect on presbyopia, from 30 minutes post dose and lasting 10 hours, with the measured outcome being the percentage of participants achieving 3 lines or more improvement in high contrast, monocular near vision (DCNVA at 40 cm) and no loss of 1 or more lines (DCDVA at 4 m) on Day 1 at all measured time points.

The FDA's own Drug Trials Snapshot describes the evidentiary basis: two clinical trials, CLARITY-1 and CLARITY-2, demonstrated efficacy by showing superiority of VIZZ over brimonidine (CLARITY-1) or vehicle (CLARITY-2) for the primary efficacy endpoint, defined as improvement of three lines (15 letters) or greater at 40 cm and no loss of 5 or more letters at 4 m in monocular Best Corrected Distant Visual Acuity at Day 1, three hours postdose. The FDA characterizes the result in measured terms: the clinical studies demonstrated that when patients with presbyopia used VIZZ as labeled, they had an improvement in seeing at a near distance when using their best corrected distance vision correction.

The magnitude and decay of effect come from the company's topline release: in the vehicle-controlled CLARITY 2 trial, Day 1 results showed rapid onset with 71% achieving three lines or greater improvement at 30 minutes, the primary endpoint of 71% achieving three lines or greater improvement at 3 hours, and long duration of 40% achieving three lines or greater improvement at 10 hours, all p<0.0001.

Safety information in the label is materially broader than the post's list. The label warns that patients may experience temporary dim or dark vision after instillation, that patients should not drive or operate machinery if vision is not clear, and that caution should be exercised in night driving and other hazardous activities in poor illumination. It further warns that rare cases of retinal tears and detachments have been reported with miotics, that examination of the retina is advised in all patients prior to initiation of therapy, that patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss, and that caution is advised in patients with a history of iritis.

Commercial status is established and past the announcement stage. LENZ's SEC filing describes the company as a commercial pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Secondary reporting of the vendor's pricing page states that VIZZ is available for $79 a month, which includes 25 doses, or $198 for three months for 75 doses, and that pricing may vary depending on pharmacy location pickup.